# Allo-HSCT as First-line Consolidation in High-risk PTCL

> **NCT03672084** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- T Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03672084
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2023-08
- **Final completion:** 2023-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672084, "Allo-HSCT as First-line Consolidation in High-risk PTCL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03672084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*